Humana Surges Following Medicare Payment Increase Announcement
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 08 2025
0mins
Should l Buy HUM?
Source: TipRanks
Humana Inc's stock rose approximately 12% in after-hours trading, reaching a 20-day high, following the Trump administration's announcement of a 2.48% increase in Medicare Advantage payments for 2027.
This significant payment increase, amounting to over $13 billion, is expected to enhance the profitability of health insurers, including Humana. The new payment rate is substantially higher than the previously proposed 0.09%, indicating strong market optimism regarding the policy shift. As more than half of Medicare beneficiaries are enrolled in Medicare Advantage plans, this change is likely to attract more beneficiaries and improve the overall market dynamics for insurers.
The implications of this announcement are profound, as it not only boosts Humana's stock but also reflects a broader positive sentiment in the health insurance sector, suggesting a potential recovery for companies that have faced challenges in the past.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy HUM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on HUM
Wall Street analysts forecast HUM stock price to rise
19 Analyst Rating
6 Buy
12 Hold
1 Sell
Moderate Buy
Current: 197.320
Low
231.00
Averages
290.39
High
344.00
Current: 197.320
Low
231.00
Averages
290.39
High
344.00
About HUM
Humana Inc. provides Humana insurance services and CenterWell health care services. The Company's segments include Insurance and CenterWell. The Insurance segment consists of Medicare benefits, marketed to individuals or directly via group Medicare accounts, as well as its contract with CMS to administer the Limited Income Newly Eligible Transition (LI-NET) prescription drug plan program and contracts with various states to provide Medicaid, dual eligible demonstration, and Long-Term Support Services benefits. This segment also includes products consisting of employer group commercial fully-insured medical and specialty health insurance benefits marketed to individuals and employer groups. The CenterWell segment includes its pharmacy, primary care, and home solutions operations. The segment also includes its strategic partnerships with WCAS to develop and operate senior-focused, payor-agnostic, primary care centers, as well as its minority ownership interest in hospice operations.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Humana Launches Pharmacist Quality Rewards Program in Ohio
- Value-Based Care Initiative: Humana Healthy Horizons launches its first Pharmacist Quality Rewards program in Ohio, designed to financially incentivize community pharmacists to close care gaps for members with hypertension and diabetes, thereby improving health outcomes for chronic condition patients.
- Key Role of Community Pharmacists: The program highlights the critical role of community pharmacists in chronic disease management, as they interact with patients more frequently than primary care providers, enabling timely identification of care gaps and necessary support for patients.
- Performance Metrics and Quality Outcomes: Participating CPESN® pharmacies will receive financial rewards based on NCQA HEDIS National Medicaid Percentiles, including controlling high blood pressure and assessing glycemic status for diabetes patients, aiming to enhance patient health management through data-driven approaches.
- Community Partnership Expansion: CPESN®USA's mission is to unite payers, pharmacies, and communities around locally delivered, value-driven care, and Humana's program demonstrates the potential of community pharmacies to significantly improve health outcomes for individuals living with chronic diseases.
See More
Humana Elects Robert S. Field to Board of Directors
- New Board Member: Humana announced the election of Robert S. Field to its Board of Directors, effective at the 2026 Annual Meeting, bringing over 20 years of healthcare investment experience that is expected to provide significant insights to the company.
- Rich Industry Background: Field previously served as a senior analyst at Luxor Capital focusing on healthcare services investments and worked as an associate at McKinsey & Company, concentrating on corporate strategy, enhancing Humana's strategic execution capabilities in the healthcare sector.
- Commitment to Board Refreshment: This appointment follows a comprehensive search process by the Humana Board, reflecting the company's ongoing commitment to board refreshment and strong corporate governance, particularly through shareholder engagement.
- Strategic Value Enhancement: Humana Chairman Kurt J. Hilzinger noted that Field's understanding of legal and regulatory dynamics will provide valuable support as the company drives sustainable growth and long-term shareholder value, further strengthening its competitive position in the market.
See More
Humana and b.well Collaborate to Enhance Health Data Access
- Health Data Network Integration: Humana's collaboration with b.well leverages a national health data network connecting 2.4 million providers and 350 health plans, enabling individuals to securely access and manage their health data, thereby enhancing patient autonomy and data transparency.
- Real-Time Data Access: Humana can access member data in real-time at the point of claims processing, supporting care coordination and quality improvement, which reduces administrative burdens and enhances the efficiency of healthcare services, ensuring providers have timely access to necessary data for high-quality care.
- Lower Administrative Costs: By reducing reliance on manual processes and duplicative documentation through standardized digital data exchange, the partnership between Humana and b.well helps lower administrative costs and inefficiencies in the healthcare system, driving more efficient workflows.
- Participation in Interoperability Demonstration: Humana and b.well are participating in an interoperability capability demonstration at the U.S. Department of Health and Human Services, showcasing live, standards-based data, which advances the accessibility and actionability of healthcare data, contributing to a future patient-directed healthcare system.
See More
BofA Raises Humana Price Target to $210 Amid Medicare Rate Hike
- Price Target Increase: BofA has raised Humana's (HUM) price target from $196 to $210 while maintaining a Neutral rating, indicating a cautiously optimistic outlook on the company's future performance.
- Impact of Medicare Policy: This price target adjustment is driven by CMS's finalization of the 2027 Medicare Advantage rates, which saw an overall increase of 2.48%, exceeding market expectations of a 1%-2% range, thus enhancing policy transparency.
- Improved Industry Outlook: The upward revision of price targets for several managed care companies suggests a growing confidence in the healthcare insurance sector, potentially attracting more investor interest in related stocks.
- Positive Market Reaction: Following CMS's announcement of the rate hike, stocks of Humana and UnitedHealth (UNH) surged, reflecting investor optimism regarding the future growth potential of the healthcare insurance industry.
See More
Alignment Healthcare Shares Surge 16.01% on Medicare Rate Increase
- Policy Boost: Alignment Healthcare's stock surged 16.01% on Tuesday, closing at $21.66 per share, as investors celebrated the higher reimbursement rates for Medicare Advantage plans, expected to yield over $13 billion in additional payments.
- Significant Rate Increase: The Centers for Medicare & Medicaid Services (CMS) reported a net average increase of 2.48% for next year's Medicare Advantage policies, a substantial rise from the 0.09% announced in January, which will directly impact the company's revenue growth.
- Optimistic Financial Outlook: Alignment Healthcare anticipates reporting first-quarter earnings with revenue targets between $5.135 billion and $5.190 billion, alongside health plan membership projections of 292,000 to 298,000, indicating robust growth potential in the market.
- Market Competition Insight: While there is optimism regarding ALHC as an investment, analysts suggest that certain AI stocks may offer greater upside potential and lower downside risk, reflecting a diverse focus on various investment opportunities in the market.
See More
Significant Increase in Medicare Advantage Payment Rates Boosts Health Insurers
- Payment Rate Increase: The CMS approved a 2.48% increase in Medicare Advantage payment rates for 2027, significantly above the initial 0.09% proposal, which is expected to provide insurers with over $13 billion in additional payments, greatly enhancing their earnings outlook.
- Positive Market Reaction: Stocks of UnitedHealth Group and Humana surged over 8% following the announcement, reflecting market optimism regarding the increase in Medicare payment rates and alleviating regulatory concerns surrounding the managed care sector.
- Improved Earnings Projections: While UnitedHealth's sales are expected to dip 1% in 2026, they are projected to rebound by 4% in 2027 to $457.29 billion, with earnings per share expected to rise 13% to $19.95, indicating a potential recovery in profitability.
- Attractive Valuations: UnitedHealth trades at a forward P/E of 15x and Humana at 18x, both below the S&P 500's 22x, with forward price-to-sales ratios under 2x, highlighting their investment appeal and drawing market interest.
See More
Humana Launches Pharmacist Quality Rewards Program in Ohio
- Value-Based Care Initiative: Humana Healthy Horizons launches its first Pharmacist Quality Rewards program in Ohio, designed to financially incentivize community pharmacists to close care gaps for members with hypertension and diabetes, thereby improving health outcomes for chronic condition patients.
- Key Role of Community Pharmacists: The program highlights the critical role of community pharmacists in chronic disease management, as they interact with patients more frequently than primary care providers, enabling timely identification of care gaps and necessary support for patients.
- Performance Metrics and Quality Outcomes: Participating CPESN® pharmacies will receive financial rewards based on NCQA HEDIS National Medicaid Percentiles, including controlling high blood pressure and assessing glycemic status for diabetes patients, aiming to enhance patient health management through data-driven approaches.
- Community Partnership Expansion: CPESN®USA's mission is to unite payers, pharmacies, and communities around locally delivered, value-driven care, and Humana's program demonstrates the potential of community pharmacies to significantly improve health outcomes for individuals living with chronic diseases.
See More
Humana Elects Robert S. Field to Board of Directors
- New Board Member: Humana announced the election of Robert S. Field to its Board of Directors, effective at the 2026 Annual Meeting, bringing over 20 years of healthcare investment experience that is expected to provide significant insights to the company.
- Rich Industry Background: Field previously served as a senior analyst at Luxor Capital focusing on healthcare services investments and worked as an associate at McKinsey & Company, concentrating on corporate strategy, enhancing Humana's strategic execution capabilities in the healthcare sector.
- Commitment to Board Refreshment: This appointment follows a comprehensive search process by the Humana Board, reflecting the company's ongoing commitment to board refreshment and strong corporate governance, particularly through shareholder engagement.
- Strategic Value Enhancement: Humana Chairman Kurt J. Hilzinger noted that Field's understanding of legal and regulatory dynamics will provide valuable support as the company drives sustainable growth and long-term shareholder value, further strengthening its competitive position in the market.
See More
Humana and b.well Collaborate to Enhance Health Data Access
- Health Data Network Integration: Humana's collaboration with b.well leverages a national health data network connecting 2.4 million providers and 350 health plans, enabling individuals to securely access and manage their health data, thereby enhancing patient autonomy and data transparency.
- Real-Time Data Access: Humana can access member data in real-time at the point of claims processing, supporting care coordination and quality improvement, which reduces administrative burdens and enhances the efficiency of healthcare services, ensuring providers have timely access to necessary data for high-quality care.
- Lower Administrative Costs: By reducing reliance on manual processes and duplicative documentation through standardized digital data exchange, the partnership between Humana and b.well helps lower administrative costs and inefficiencies in the healthcare system, driving more efficient workflows.
- Participation in Interoperability Demonstration: Humana and b.well are participating in an interoperability capability demonstration at the U.S. Department of Health and Human Services, showcasing live, standards-based data, which advances the accessibility and actionability of healthcare data, contributing to a future patient-directed healthcare system.
See More
BofA Raises Humana Price Target to $210 Amid Medicare Rate Hike
- Price Target Increase: BofA has raised Humana's (HUM) price target from $196 to $210 while maintaining a Neutral rating, indicating a cautiously optimistic outlook on the company's future performance.
- Impact of Medicare Policy: This price target adjustment is driven by CMS's finalization of the 2027 Medicare Advantage rates, which saw an overall increase of 2.48%, exceeding market expectations of a 1%-2% range, thus enhancing policy transparency.
- Improved Industry Outlook: The upward revision of price targets for several managed care companies suggests a growing confidence in the healthcare insurance sector, potentially attracting more investor interest in related stocks.
- Positive Market Reaction: Following CMS's announcement of the rate hike, stocks of Humana and UnitedHealth (UNH) surged, reflecting investor optimism regarding the future growth potential of the healthcare insurance industry.
See More
Alignment Healthcare Shares Surge 16.01% on Medicare Rate Increase
- Policy Boost: Alignment Healthcare's stock surged 16.01% on Tuesday, closing at $21.66 per share, as investors celebrated the higher reimbursement rates for Medicare Advantage plans, expected to yield over $13 billion in additional payments.
- Significant Rate Increase: The Centers for Medicare & Medicaid Services (CMS) reported a net average increase of 2.48% for next year's Medicare Advantage policies, a substantial rise from the 0.09% announced in January, which will directly impact the company's revenue growth.
- Optimistic Financial Outlook: Alignment Healthcare anticipates reporting first-quarter earnings with revenue targets between $5.135 billion and $5.190 billion, alongside health plan membership projections of 292,000 to 298,000, indicating robust growth potential in the market.
- Market Competition Insight: While there is optimism regarding ALHC as an investment, analysts suggest that certain AI stocks may offer greater upside potential and lower downside risk, reflecting a diverse focus on various investment opportunities in the market.
See More
Significant Increase in Medicare Advantage Payment Rates Boosts Health Insurers
- Payment Rate Increase: The CMS approved a 2.48% increase in Medicare Advantage payment rates for 2027, significantly above the initial 0.09% proposal, which is expected to provide insurers with over $13 billion in additional payments, greatly enhancing their earnings outlook.
- Positive Market Reaction: Stocks of UnitedHealth Group and Humana surged over 8% following the announcement, reflecting market optimism regarding the increase in Medicare payment rates and alleviating regulatory concerns surrounding the managed care sector.
- Improved Earnings Projections: While UnitedHealth's sales are expected to dip 1% in 2026, they are projected to rebound by 4% in 2027 to $457.29 billion, with earnings per share expected to rise 13% to $19.95, indicating a potential recovery in profitability.
- Attractive Valuations: UnitedHealth trades at a forward P/E of 15x and Humana at 18x, both below the S&P 500's 22x, with forward price-to-sales ratios under 2x, highlighting their investment appeal and drawing market interest.
See More
